To compare the Pharmacokinetics (PK) / Pharmacodynamics(PD)of a single subcutaneous (sc) injection (3.6 mg) of MYL-1401H and G-Lasta in Japanese healthy adult volunteers

开始日期2022-03-17

申办/合作机构-

NCT05573386 / RecruitingN/A

A Single Center, Prospective Study to Compare the Quality and Quantity of the Cellular Content of M-PRP Harvested After Peripheral Mobilization of Progenitor Cells Using Filgrastim Versus Pegfilgrastim

The goal of this prospective, observational study is to compare the quality and quantity of the cellular content of platelet-rich plasma harvested after administering one of two cell-stimulating proteins, filgrastim and pegfilgrastim. The main question it aims to answer is:
• Will participants have a similar cellular content when comparing a 4-day filgrastim treatment to a one-day pegfilgrastim treatment?
Participants will have the following intervention administered:
130mL of blood will be drawn on the first visit after consent and in followup visits after administering treatment (4 days for filgrastim, 7 days for pegfilgrastim)
Half of all participants will receive filgrastim first, followed by pegfilgrastim 8 weeks after filgrastim treatment concludes. The other half will receive the treatments in reverse order
Researchers will compare the quality and quantity of cell content after each treatment administration as well as comparing differences in data dependent on which order treatment was given.

开始日期2021-08-09

申办/合作机构

Andrews Research & Education Foundation, Inc.初创企业

IRCT20180119038433N3 / Suspended临床3期

Comparison of the effect of pegfilgrastim with filgrastim on the neutrophil count of cancer patients under chemotherapy, a randomization clinical trial.

开始日期2020-10-22

申办/合作机构

Semnan University

100 项与培非格司亭生物类似药（Biocon）相关的临床结果

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的转化医学

登录后查看更多信息

100 项与培非格司亭生物类似药（Biocon）相关的专利（医药）

登录后查看更多信息

项与培非格司亭生物类似药（Biocon）相关的文献（医药）

2023-02-01·Journal of Managed Care & Specialty Pharmacy

Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study

Article

作者: Vouri, Scott M ; Wang, Ching-Yu ; Brown, Joshua D ; Heldermon, Coy D ; Park, Haesuk

BACKGROUND: Real-world evidence on the comparative effectiveness of pegfilgrastim biosimilars compared with the originator product is limited. OBJECTIVE: To compare the risk of febrile neutropenia (FN) among users of pegfilgrastim biosimilars (pegfilgrastim-jmdb and pegfilgrastim-cbqv) and the originator product. METHODS: A retrospective cohort study was conducted using 2019 IBM MarketScan databases to assess comparative effectiveness of pegfilgrastim originator and biosimilars for prevention of FN among patients receiving myelosuppressive chemotherapy. Patients with cancer, including breast, lung, colorectal, esophageal and gastric, pancreatic, prostate, ovarian, and non-Hodgkin lymphomas, initiating myelosuppressive chemotherapy courses were selected. We further selected patients who used pegfilgrastim originator and biosimilars within 3 days of chemotherapy completion. FN-associated hospitalizations were measured by International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis codes. After 1:1 propensity score matching, we used equivalence (with a margin of 6%) hypothesis tests to compare FN-related hospitalization risk in the first cycle and across all cycles between biosimilars and originator users. RESULTS: A total of 2,045 patients were included, of which 445 (21.8%) used pegfilgrastim-jmdb, 636 (31.1%) used pegfilgrastim-cbqv, and 964 (47.1%) used pegfilgrastim originator. After matching, 13 out of 445 originator users and 17 out of 445 pegfilgrastim-jmdb users developed FN after the first chemotherapy cycle (risk difference was 0.9%; P < 0.001 for equivalence test indicating statistical equivalence). After matching, 14 out of 633 originator users and 16 out of 633 pegfilgrastim-cbqv users developed FN (risk difference was 0.32%; P < 0.001 for equivalence test indicating statistical equivalence). Results across all cycles (including the first cycle) were consistent with that in the first cycle. CONCLUSIONS: In this real-world study of patients with cancer receiving myelosuppressive chemotherapy, there was no difference in FN risk between patients receiving pegfilgrastim originator and biosimilars in the first cycle and across all cycles. These results add further to the current evidence on pegfilgrastim biosimilars and support wider adoption of pegfilgrastim biosimilars among payers, providers, and patients. Future studies assessing the tolerability, side effects, and other safety issues of pegfilgrastim biosimilars are needed.

2022-07-01·Journal of Managed Care & Specialty Pharmacy

Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population

Article

作者: Vouri, Scott M ; Wang, Ching-Yu ; Brown, Joshua D ; Park, Haesuk ; Heldermon, Coy D

BACKGROUND: It is unknown whether using pegfilgrastim biosimilars is cost saving in a real-world setting. OBJECTIVE: To compare medical costs including pegfilgrastim drug costs and febrile neutropenia (FN) treatment and management costs between pegfilgrastim biosimilars (pegfilgrastim-jmdb, pegfilgrastim-cbqv) and originator users for primary prophylaxis of febrile neutropenia. METHODS: A retrospective cohort study using 2019 IBM MarketScan Commercial and Medicare Supplemental databases was conducted in adult patients with cancer initiating myelosuppressive chemotherapy courses. At least 2 diagnoses of the same cancer (at least 7 days apart) were required within 30 days of the chemotherapy initiation date. Pegfilgrastim (excluding on-body injector) costs included drug costs only (excluding administration fees). FN-related costs included all FN-related health care utilizations that were defined as having neutropenia, fever, or infection diagnosis. Per-patient per-cycle (PPPC) out-of-pocket (OOP) costs, health plan costs, and total costs were compared between originator (excluding on-body injector) and biosimilars users in the first cycle. A generalized linear model and a 2-part model were used. RESULTS: A total of 1,930 patients were included, of whom 884 (45.8%) used pegfilgrastim originator, 427 (22.1%) used pegfilgrastim-jmdb, and 619 (32.1%) used pegfilgrastim-cbqv. Adjusted PPPC OOP pegfilgrastim costs in the first cycle were significantly lower for the biosimilars vs the originator ($182 for pegfilgrastim-jmdb and $159 for pegfilgrastim-cbqv vs $299 for originator, P < 0.0001 for both comparisons). However, there was no difference in health plan costs ($5,783 for pegfilgrastim-jmdb and $5,845 for pegfilgrastim-cbqv vs $5,618 for originator) and total costs. In addition, no difference was observed for adjusted PPPC FN treatment and management OOP costs, health plan costs, and total costs in the first cycle. FN treatment OOP costs were $192 for originator, $197 for pegfilgrastim-jmdb (P = 0.958), and $240 for pegfilgrastim-cbqv (P = 0.680). FN treatment health plan costs were $2,804 for originator, $2,970 for pegfilgrastim-jmdb (P = 0.692), and $2,745 for pegfilgrastim-cbqv (P = 0.879). CONCLUSIONS: In a commercially insured population, using pegfilgrastim biosimilars in the first cycle for primary prophylaxis of FN led to cost savings for patients but not payers. No difference in FN-related costs was observed.

2021-03-01·BioDrugs3区 · 医学

Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

3区 · 医学

Article

作者: Almahasis, Sura ; Qian, Jingjing ; Tanni, Kaniz Afroz ; Truong, Cong Bang

BACKGROUNDSince the approval and availability of the first biosimilar in 2015 in the United States (US), evidence regarding the post-marketing safety of cancer supportive care biosimilars remains limited.OBJECTIVEThe aim was to explore the adverse event (AE) reporting patterns and detect disproportionate reporting signals for cancer supportive care biosimilars in the US compared to their originator biologics.METHODSThe US Food and Drug Administration Adverse Event Reporting System database (January 1, 2004-March 31, 2020) was used to identify AE reports for filgrastim, pegfilgrastim, and epoetin alpha by type of product (originator biologics vs. biosimilars) and report characteristics. Plots of AE reports against years were used to reveal the reporting patterns. Disproportionality analyses using reporting odds ratios (RORs) were conducted to detect differences in serious and specific AEs between studied drugs and all other drugs. Breslow-Day tests were used to determine homogeneity between the originator biologic-biosimilar pair RORs for the same AE.RESULTSTotal numbers of AEs for all studied biosimilars increased after marketing. More AE reports were from female patients for all of the studied drugs. More AEs for originator biologics and filgrastim biosimilar were reported by health professionals, while the highest proportion of reports came from consumers for pegfilgrastim and epoetin alpha biosimilars (29% and 44.1%, respectively). Signals of disproportionate reporting in serious AEs were detected for a pegfilgrastim biosimilar (Fulphila^®) compared to its originator biologic.CONCLUSIONOur findings support the similarity in the signals of disproportionate reporting between cancer supportive care originator biologics and biosimilars, except for Fulphila^®.

项与培非格司亭生物类似药（Biocon）相关的新闻（医药）

2024-03-07

·PRNewswire

United States Biosimilar industry Outlook to 2028, Featuring Pfizer, Amgen, Biogen, Viatris and Coherus Biosciences

DUBLIN, March 7, 2024 /PRNewswire/ -- The "US Biosimilar industry outlook to 2028" report has been added to ResearchAndMarkets.com's offering. The US Biosimilar Industry is anticipated to grow at a CAGR of ~40% in the next five years owing to the cost-effective nature of Biosimilar drugs, rising geriatric population, increasing cases of chronic diseases and growing strategic partnerships. The US Biosimilar market is significantly growing due to various reasons such as rising geriatric population, cost effective nature of Biosimilar drugs, increasing cases of chronic diseases and growing strategic partnerships. Biosimilar drugs also tend to be cost effective. The geriatric population in the US has been constantly rising. The ageing population went from ~25,000 per 100,000 people in 1980s to ~54,000 per 100,000 people in 2020s. Most of the aged people cannot afford original drugs and thus, rising geriatric population raises the demand for Biosimilar drugs. Moreover, the cases of chronic diseases also have been rising in the US over the years. In 2020, there were at least 155 million people living with a chronic disease in the US. Such high number of chronic illness cases also raise the demand for the development of cost-effective medicines in the form of Biosimilar drugs. Key trends by Market Segment: By Drug class: In 2022, Monoclonal Antibodies continued to dominate the US Biosimilar Market. These antibodies can be best described as proteins developed in laboratories that are known to act like actual antibodies present in our blood. The reason behind their dominance is that they have been very successful when it comes to treating life threatening diseases such as cancers. Moreover, a treatment involving these antibodies happens to be more precise than any other treatment. Furthermore, these antibodies are known for activating the immune responses for fighting a particular disease. Due to their success rates and ability to stimulate immune responses, they have gained quite a popularity in the US Biosimilar market. By Application: In 2022, Oncology segment dominated the US Biosimilar market. The cancer cases have been rapidly rising in the United States over the years. In 2022, the United State witnessed almost 2 million cancer cases. The rising cases of cancer also results in the demand for the development of effective and efficient treatment of cancer. Monoclonal Antibodies that are used in Biosimilar drugs also have a 58% success rate in treating cancer. Overall, Biosimilar drugs are widely used in the treatment of various types of cancers such as breast cancer, lung cancer, colorectal cancer, etc. There are many Biosimilar drugs such as Zirabev, Truxima, Ogiviri, Releuko, Fulphila, Retacrit, etc which are used in the effective and efficient treatment of Cancer. By Geography: In 2022, the northern region of US happened to be the dominant segment in the US Biosimilar market. The main reason behind its dominance is the presence of Biosimilar drugs manufacturing companies, presence of many other healthcare companies and top-notch hospitals of the country. This is primarily due to the reason that this region witnesses the major healthcare companies of Biosimilar market in the country such as Amgen, Pfizer, Viartis, Biogen, Coherus Biosciences etc. Overall, there are almost 9000 healthcare companies established in this area. Due to the presence of vast number of companies, this region contributes to the growth of US Biosimilar market greatly. There are also many reputed hospitals located in this area such as Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Centre, Dana Farber Cancer Institute, Hospitals of University of Pennsylvania, Northwestern Memorial Hospital, Barns-Jewish Hospital, etc. As more and more people visits these hospitals, the healthcare professionals get to know the requirements and demands of the Biosimilar drugs thereby accelerating the US Biosimilar Market. Future Outlook: The US Biosimilar Market is anticipated to witness a growth at a CAGR of 40% between the time period 2022-2028 owing to the rising cases of chronic diseases, rising geriatric population and increasing cases of cancer along with growing strategic partnerships among pharmaceutical companies. The prevalence of chronic diseases have been constantly rising in the United States. In 2020, there were at least 155 million people living with a chronic disease. This number is futher projected to reach 165 million and 170 million in 2025 and 2030 respectively. With rapidly rising cases, the demand for biosimilar drugs will be rising thereby driving the US Biosimilar market. The rising geriatric population also increases the demand for Biosimilar drugs. In the US, the geriatric population has increased from 25 per 100 people in the 1980s to 54 per 100 people in 2020. This number is further anticipated to reach 72 per 100 people in 2030s. With rising geriatric population, the demand for Biosimilar drugs rises as aged population is less likely to afford generic drugs. The rising cases of cancer also have resulted in an increased demand for Biosimilar drugs. Cancer has been rapidly rising in the US with around 2 million cases in 2020. The number is only projected to further increase. Moreover, most of the Biosimilar drugs are used in oncology so the rising cases only increases the demand for Biosimilar drugs thereby fueling the US Biosimilar market. Key Topics Covered: 1. Executive Summary 2. US Biosimilar Market Overview 2.1 Taxonomy of the Market 2.2 Industry Value Chain 2.3 Ecosystem 2.4 Government Regulations/Initiatives for the Market 2.5 Growth Drivers of the US Biosimilar Market 2.6 Issues and Challenges of the US Biosimilar Market 2.7 Impact of COVID-19 on US Biosimilar Market 2.8 SWOT Analysis 3.US Biosimilar Market Size, 2017 - 2022 4. US Biosimilar Market Segmentation 4.1 By Drug Class, 2017 - 2022 4.2 By Application 2017 - 2022 4.3 By Regional Split (North/East/West/South/Central), 2017 - 2022 5. Competitive Landscape 5.1 Mergers and Acquisitions, Joint Ventures, Collaborations, and Agreements 5.2 Strategies Adopted by Leading Players 5.3 Company Profiles Pfizer Amgen Biogen Viatris Coherus Biosciences 6. US Biosimilar Market, 2022-2028 7. US Biosimilar Market, Market Segmentation 7.1 By Drug class, 2022 - 2028 7.2 By Application, 2022 - 2028 7.3 By Regional Split (North/East/West/South/Central), 2022 - 2028 8. Analyst Recommendations For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

生物类似药

2023-12-18

·美通社

Biocon Biologics 完成其在约 120 个国家/地区所收购的生物仿制药业务的整合

超过 10 个新兴市场、日本、澳大利亚和新西兰的过渡进程已进入最终阶段马来西亚吉隆坡 2023年12月18日 /美通社/ -- 作为一家独特的全球生物仿制药一体化企业， Biocon Biologics 有着广泛的胰岛素和单克隆抗体产品组合。该公司已成功完成对收购的 Viatris 生物仿制药业务的整合，其在超过 10 个新兴市场以及日本、澳大利亚及新西兰的过渡进程已进入最终阶段。 PFA the banner image 包括 Ogivri® 和 Hertraz® (bTrastuzumab)、Abevmy® (bBevacizumab)、Fulphila® (bPegfilgrastim)、Hulio® (bAdalimumab)、Nepexto® (bEtanercept)、Semglee® (bGlargine) 及 Kirsty® (bAspart) 在内的 Viatris 旗下所有生物仿制药品牌现已整合到 Biocon Biologics 在高级市场和 80 多个新兴市场的商业特许经营业务中。这些产品主要由 Biocon Biologics 开发，并在其位于印度和马来西亚的世界级工厂进行生产。目前，Biocon Biologics 在约 120 个国家/地区建立了强大的商业品牌，其直接业务覆盖美国、加拿大、欧洲，以及印度、阿联酋、沙特阿拉伯、摩洛哥、南非、巴西、马来西亚、泰国和菲律宾等 9 个主要新兴市场国家/地区。 "能够完成我们在 120 个国家/地区所收购业务的成功整合，我感到极为自豪和激动。过渡最终阶段的完成是 Biocon Biologics 向全球一体化公司转型的重大里程碑及标志。我对整个 Biocon Biologics 团队——同事、顾问及合作伙伴表示祝贺和感谢。提前完成无缝过渡，要归功于我们对患者和业务持续性的不懈关注、持续努力和坚定承诺。"—— 首席行政官兼行销总监 Shreehas Tambe 表示。 "我们的团队将借助这一重要里程碑所带来的独特机遇，将 Biocon Biologics 品牌直接推向众多市场。该自主引导的商业模式将使我们与患者、卫生部门、处方医师和付费人之间的联系更加密切。这将使我们有能力以经济实惠的价格为更多患者群体服务，同时为新兴市场的医疗保健系统大幅节约成本，从而实现高品质生物仿制药的公平获取。"—— 新兴市场首席商务官 Susheel Umesh 表示。 Biocon Biologics 已经进行了多项关键领导层任命，重新构建了新的能力和基础设施，并成立了专业化团队，利用自主经营和合作伙伴或分销商主导的商业模式，以满足患者和客户日益增长的需求，确保患者、处方医师、合作伙伴和医疗保健系统之间业务连续性。网站： www.bioconbiologics.com；Twitter： @BioconBiologics；LinkedIn： Biocon Biologics

并购

2023-12-18

·PRNewswire

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

10+ Emerging Markets, Japan & ANZ Transition in Final Phase DUBAI, UAE, Dec. 18, 2023 /PRNewswire/ -- Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase. Continue Reading PFA the banner image (PRNewsfoto/Biocon Biologics Ltd) All Viatris' biosimilars brands, including Ogivri® & Hertraz® (bTrastuzumab), Abevmy® (bBevacizumab), Fulphila® (bPegfilgrastim), Hulio® (bAdalimumab), Nepexto® (bEtanercept), Semglee® (bGlargine) and Kirsty® (bAspart) are now part of Biocon Biologics' commercial franchise in Advanced Markets and 80+ Emerging Markets. Most of these products have been developed by Biocon Biologics and are being manufactured at its world-class facilities in India and Malaysia. Biocon Biologics will now have a strong commercial footprint across ~120 countries with a direct presence in the U.S., Canada, Europe and 9 key Emerging Market countries of India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines. "I am very proud and excited that we have successfully completed the integration of the acquired business across 120 countries. The conclusion of this final wave of transition is a significant milestone and marks the beginning of Biocon Biologics' transformation to a fully integrated global company. I congratulate and thank the entire Biocon Biologics team – colleagues, advisors, and partners. This seamless transition, achieved ahead of schedule, is an outcome of relentless focus, untiring efforts and an unwavering commitment to patients and business continuity." - Shreehas Tambe, CEO & Managing Director. "This milestone presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets. This self-led business model will take us closer to the patients, MoHs, prescribers and payers. It will allow us to expand affordable access to larger patient pools and generate significant savings for healthcare systems in these emerging markets, thus enabling equitable access to high quality biosimilars." - Susheel Umesh, Chief Commercial Officer - Emerging Markets. Biocon Biologics has made several key leadership appointments, built new capabilities and infrastructure from the ground up and set up dedicated teams to address the growing needs of patients and customers through self-led and partner or distributor-led commercial models to ensure business continuity for patients, prescribers, partners, and healthcare systems. Website: ; Twitter: @BioconBiologics; LinkedIn: Biocon Biologics SOURCE Biocon Biologics Ltd

并购高管变更上市批准

100 项与培非格司亭生物类似药（Biocon）相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AA13	DB00019

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
粒细胞减少性发热	冰岛	Biosimilar Collaborations Ireland Ltd.	2018-11-20
粒细胞减少性发热	列支敦士登	Biosimilar Collaborations Ireland Ltd.	2018-11-20
粒细胞减少性发热	挪威	Biosimilar Collaborations Ireland Ltd.	2018-11-20
粒细胞减少性发热	欧盟	Biosimilar Collaborations Ireland Ltd.	2018-11-20
中性粒细胞减少	挪威	Biosimilar Collaborations Ireland Ltd.	2018-11-20
中性粒细胞减少	列支敦士登	Biosimilar Collaborations Ireland Ltd.	2018-11-20
中性粒细胞减少	冰岛	Biosimilar Collaborations Ireland Ltd.	2018-11-20
中性粒细胞减少	欧盟	Biosimilar Collaborations Ireland Ltd.	2018-11-20
化疗引起的发热性中性粒细胞减少症	美国	Mylan Pharmaceuticals, Inc.	2018-06-04
化疗引起的发热性中性粒细胞减少症	美国	Biocon Biologics Ltd. (India)	2018-06-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	匈牙利	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	乌克兰	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	格鲁吉亚	Mylan, Inc.	2015-03-01
乳腺癌	临床3期	德国	Mylan, Inc.	2015-03-01
化疗引起的发热性中性粒细胞减少症	临床3期	印度	Biocon Ltd.	-
乳腺癌	临床1期	波兰	Mylan, Inc.	2015-03-01
乳腺癌	药物发现	保加利亚	Mylan, Inc.	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2019	N/A	转移性结直肠癌	-	Pegfilgrastim-treated	(鏇獵鑰顧窪廠鬱構艱遞) = 簾鑰夢艱願廠壓鹹網襯壓觸觸願醖簾願淵蓋壓 (遞築鹹鏇壓醖蓋鬱艱築 ) 更多	不佳	2019-05-26
				pegfilgrastim (Peg-untreated)	(鏇獵鑰顧窪廠鬱構艱遞) = 壓艱憲夢鏇獵蓋簾觸鹹壓觸觸願醖簾願淵蓋壓 (遞築鹹鏇壓醖蓋鬱艱築 ) 更多
NCT01671319 (CTgov)	临床2期	乳腺癌	42	pegfilgrastim+cyclophosphamide+docetaxel	憲膚鏇繭艱醖繭鏇廠蓋(醖窪簾廠鬱製糧簾窪蓋) = 襯遞齋衊簾選製淵淵鹹鹹廠蓋製積鑰壓積製獵 (構鑰鹽艱簾膚淵遞鑰廠, 願範願鏇鹹鑰範顧醖衊 ~ 構製憲壓選觸淵獵壓膚) 更多	-	2017-10-12
ASCO2006	N/A	乳腺癌	14	Docetaxel + Epirubicin + pegfilgrastim	蓋膚壓鑰鏇鬱簾膚齋糧(壓鏇鑰構齋艱網艱網膚) = 壓鬱蓋觸齋鹽憲廠繭繭壓衊鑰夢憲衊觸選獵壓 (顧餘衊築餘範齋鹽鏇醖 )	-	2006-06-20
ESMO_ASIA2022	N/A	侵袭性非霍奇金淋巴瘤	263	PEG G-CSF	(製衊蓋夢壓繭壓糧餘夢) = 鹹蓋鏇淵製衊觸壓衊淵鏇齋壓蓋壓鹹遞願壓夢 (構顧蓋壓獵壓窪製膚簾 ) 更多	-	2022-12-03
				Non-PEG G-CSF	(製衊蓋夢壓繭壓糧餘夢) = 壓築簾淵簾蓋顧糧襯鹹鏇齋壓蓋壓鹹遞願壓夢 (構顧蓋壓獵壓窪製膚簾 ) 更多
NCT02142049 (CTgov)	临床1/2期	难治性弥漫性大 B 细胞淋巴瘤 \| 弥漫性大B细胞淋巴瘤 \| 复发性弥漫性大B细胞淋巴瘤	35	Etoposide+Ibrutinib+Cyclophosphamide+Pegfilgrastim+Prednisone+Doxorubicin+Rituximab+Vincristine (Part 1: Dose Level 1)	(膚鏇顧顧醖鬱選簾鏇淵) = 鬱糧淵醖製蓋製遞餘憲糧顧遞獵蓋網鹽壓襯廠 (鏇築蓋築憲餘獵艱廠艱, 鏇網築夢餘簾糧膚範獵 ~ 範鬱夢製衊觸襯鹹網遞) 更多	-	2019-02-05
				Lenalidomide+Etoposide+Ibrutinib+Cyclophosphamide+Pegfilgrastim+Prednisone+Doxorubicin+Rituximab+Vincristine (Part 1: Dose Level 2)	(膚鏇顧顧醖鬱選簾鏇淵) = 壓願鑰選獵衊糧構鑰簾糧顧遞獵蓋網鹽壓襯廠 (鏇築蓋築憲餘獵艱廠艱, 餘憲簾顧廠壓憲積襯壓 ~ 觸鹹構齋繭衊廠鹽範構) 更多
ASCO2023	N/A	局部晚期乳腺癌新辅助	62	TCHP and pegfilgrastim	(壓積鏇蓋醖鹹範糧襯網) = 憲夢繭憲遞壓鏇鹹憲夢鹽艱窪廠餘鹽鹹蓋艱齋 (窪繭鬱鹽築範餘鹽鹽簾 )	积极	2023-05-31
NCT02467868 (Pubmed) 人工标引	临床3期	中性粒细胞减少	135	MYL-1401H	(鏇夢齋顧餘繭餘蓋鏇壓) = 蓋積壓繭衊鏇蓋鹽蓋艱製廠選蓋範醖憲獵憲鹽 (簾夢襯鹹願膚窪憲糧衊, 0.93) 更多	相似	2019-05-01
				pegfilgrastim	(鏇夢齋顧餘繭餘蓋鏇壓) = 鏇蓋鬱網構艱醖壓壓築製廠選蓋範醖憲獵憲鹽 (簾夢襯鹹願膚窪憲糧衊, 1.10) 更多
ASCO2004	临床2期	广泛期小细胞肺癌	30	ACE chemotherapy + pegfilgrastim	(艱壓壓淵網獵淵憲觸遞) = 膚積齋醖襯窪餘築繭餘遞繭憲範蓋醖鑰醖艱糧 (構繭膚鑰鬱衊顧襯簾獵 ) 更多	-	2004-07-15